+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

  • ID: 4575960
  • Report
  • June 2018
  • Region: Global
  • 223 Pages
  • La Merie Publishing

Intracellular cancer targets are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy.

The six reports of this package are covering immunotherapeutics against six important intracellular cancer targets:

  • Melanoma-associated antigen A: MAGE-A
  • New York esophageal squamous cell carcinoma-1: NY-ESO-1
  • Human telomerase reverse transcriptase: hTERT
  • Wilms‘ tumor 1: WT1
  • Preferentially expressed antigen in melanoma: PRAME
  • Survivin

This report package includes six Competitor Analysis reports covering immunotherapeutics directed to six different important cancer targets.

The original reports were published in May and June 2018, respectively:

  • Competitor Analysis: MAGE-A-Targeted Immunotherapy
  • Competitor Analysis: NY-ESO-1-Targeted Immunotherapy
  • Competitor Analysis: hTERT-Targeted Immunotherapy
  • Competitor Analysis: WT1-Targeted Immunotherapy
  • Competitor Analysis: PRAME-Targeted Immunotherapy
  • Competitor Analysis: Survivin-Targeted Immunotherapy

*Detailed report descriptions and tables of contents from the reports can be found on the respective product pages, which can be found in the "Also available" Section below.The reports can be acquired separately or as a package with a 40% discount on list prices.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Note: Product cover images may vary from those shown

Competitor Analysis: MAGE-A-Targeted Immunotherapy

1. MAGE-A-Targeted Immunotherapy:

  • MAGE-A1
  • MAGE-A3
  • MAGE-A4
  • MAGE-A6
  • MAGE-A10
  • MAGE-A12

2. Corporate & Institutional MAGE-A Immunotherapy R&D Pipelines

Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

1. NY-ESO-1-Targeted Immunotherapy

  • NY-ESO-1 Selective Cancer Vaccines
  • NY-ESO-1 Specific, Multi-Target Cancer Vaccines
  • NY-ESO-1 Selective Adoptive Cell Therapy
  • NY-ESO-1 Specific, Multi-Target Adoptive Cell Therapy
  • NY-ESO-1 Selective Recombinant Antibodies & Proteins

2. Corporate & Institutional NY-ESO-1 Immunotherapy R&D Pipelines

Competitor Analysis: hTERT-Targeted Immunotherapy

1. hTERT-Targeted Immunotherapy

  • hTERT-Selective Cancer Vaccines
  • hTERT-Specific, Multi-Target Cancer Vaccines
  • hTERT-Targeted Adoptive Cell Therapy
  • Other hTERT-Targeted Immunotherapies

2. Corporate & Institutional hTERT Immunotherapy R&D Pipelines

Competitor Analysis: WT1-Targeted Immunotherapy

1. WT1-Targeted Immunotherapy

  • Selective WT1-Targeted Vaccines
  • WT1-Specific, Multi-Target Vaccines
  • WT1-Selective Adoptive Cell Therapy
  • WT1-Specific, Multi-Target Adoptive Cell Therapy
  • WT1-Targeted Antibodies

2. Corporate & Institutional WT1 Immunotherapy R&D Pipelines

Competitor Analysis: PRAME-Targeted Immunotherapy

1. PRAME-Targeted Immunotherapy

  • PRAME-Targeted Selective and Multi-Antigen Cancer Vaccines
  • PRAME-Selective Cellular & Recombinant Immunotherapies
  • PRAME-Specific, Multi-Target Adoptive Cell Therapy

2. Corporate & Institutional PRAME Immunotherapy R&D Pipelines

Competitor Analysis: Survivin-Targeted Immunotherapy

1. Survivin-Targeted Immunotherapy

  • Survivin-Selective Cancer Vaccines
  • Survivin-Specific, Multi-Antigen Cancer Vaccines
  • Survivin-Selective Adoptive T-Cell Therapy & Oncolytic Viral Immunotherapy
  • Survivin-Specific, Multi-Target Adoptive T-Cell Therapy

2. Corporate Survivin Immunotherapy R&D Pipelines

Note: Product cover images may vary from those shown